For research use only. Not for therapeutic Use.
ENMD-1198 (Cat.No:I006674) is a small molecule inhibitor that targets angiogenesis, the formation of new blood vessels. It inhibits the activity of tyrosine kinase receptors involved in angiogenesis, leading to suppression of tumor growth and metastasis. ENMD-1198 shows potential as an anti-cancer agent in preclinical studies, highlighting its therapeutic significance.
| Catalog Number | I006674 |
| CAS Number | 864668-87-1 |
| Synonyms | ENMD 1198; ENMD1198; Estra135(10)16tetraene3carboxamide 2methoxy; 2Methoxy135(10)16estratetraene3carboxamide; IRC 110160.;(13R)-2-methoxy-13-methyl-7,8,9,11,12,13,14,15-octahydro-6H-cyclopenta[a]phenanthrene-3-carboxamide |
| Molecular Formula | C20H25NO2 |
| Purity | ≥95% |
| Target | Cytoskeleton |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | (8S,9S,13R,14S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthrene-3-carboxamide |
| InChI | InChI=1S/C20H25NO2/c1-20-8-3-4-17(20)14-6-5-12-10-16(19(21)22)18(23-2)11-15(12)13(14)7-9-20/h3,8,10-11,13-14,17H,4-7,9H2,1-2H3,(H2,21,22)/t13?,14?,17?,20-/m0/s1 |
| InChIKey | YQJWOUQGXATDAE-CBTMWXCYSA-N |
| SMILES | O=C(C1=C(OC)C=C2C3CC[C@]4(C)C=CCC4C3CCC2=C1)N |
| Reference | </br>1:2-methoxyestradiol analogue ENMD-1198 reduces breast cancer-induced osteolysis and tumor burden both in vitro and in vivo. Snoeks TJ, Mol IM, Que I, Kaijzel EL, Löwik CW.Mol Cancer Ther. 2011 May;10(5):874-82. doi: 10.1158/1535-7163.MCT-10-0997. Epub 2011 Mar 21. PMID: 21422268 Free Article</br>2:ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Pasquier E, Sinnappan S, Munoz MA, Kavallaris M.Mol Cancer Ther. 2010 May;9(5):1408-18. doi: 10.1158/1535-7163.MCT-09-0894. Epub 2010 May 4. PMID: 20442304 Free Article</br>3:A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR.Invest New Drugs. 2011 Apr;29(2):340-6. doi: 10.1007/s10637-009-9383-9. Epub 2010 Jan 19. PMID: 20084425 Free PMC Article</br>4:ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler WE, Stoeltzing O.BMC Cancer. 2008 Jul 23;8:206. doi: 10.1186/1471-2407-8-206. PMID: 18651980 Free PMC Article</br>5:Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM.Mol Cancer Ther. 2008 Jun;7(6):1472-82. doi: 10.1158/1535-7163.MCT-08-0107. PMID: 18566218 Free Article |
